Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Abstract The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antige...

Full description

Bibliographic Details
Main Authors:	Ming-Ying Lu, Chun-Ting Chen, Yu-Lueng Shih, Pei-Chien Tsai, Meng-Hsuan Hsieh, Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Shu-Chi Wang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Wen-Yu Chang
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-04-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-87975-5

Similar Items

Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinoma
by: Kuan‐I Lee, et al.
Published: (2023-11-01)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients
by: Ching-I Huang, et al.
Published: (2017-08-01)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
by: Tsai Jung-Fa, et al.
Published: (2005-04-01)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
by: Chuan-Pin Lin, et al.
Published: (2021-01-01)

Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma
by: Ming-Lun Yeh, et al.
Published: (2015-02-01)

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection
by: Chung-Feng Huang, et al.
Published: (2015-05-01)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma.
by: Ming-Lun Yeh, et al.
Published: (2017-01-01)

Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan
by: Pei‐Chien Tsai, et al.
Published: (2022-07-01)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)

Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
by: Tyng-Yuan Jang, et al.
Published: (2021-01-01)

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
by: Tyng-Yuan Jang, et al.
Published: (2021-04-01)

Itemization difference of patient-reported outcome in patients with chronic liver disease
by: Ming-Chieh Lin, et al.
Published: (2022-01-01)

Association of hyperuricemia with disease severity in chronic hepatitis C patients.
by: Tyng-Yuan Jang, et al.
Published: (2018-01-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
by: Chung-Feng Huang, et al.
Published: (2021-01-01)

Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients
by: Tyng‐Yuan Jang, et al.
Published: (2022-03-01)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
by: Yi-Shan Tsai, et al.
Published: (2022-04-01)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
by: Yi-Shan Tsai, et al.
Published: (2020-07-01)

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
by: Po-Yao Hsu, et al.
Published: (2021-01-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.
by: Tyng-Yuan Jang, et al.
Published: (2017-01-01)

The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
by: Jia-Jung Lee, et al.
Published: (2020-01-01)

Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
by: Ming‐Lun Yeh, et al.
Published: (2021-02-01)

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.
by: Chung-Feng Huang, et al.
Published: (2013-01-01)

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2015-01-01)

Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma
by: Zu‐Yau Lin, et al.
Published: (2021-07-01)

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression
by: Zu‐Yau Lin, et al.
Published: (2022-02-01)

Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
by: Chung‐Feng Huang, et al.
Published: (2020-11-01)

Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
by: Chung‐Feng Huang, et al.
Published: (2024-04-01)

Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]
by: Chung-Feng Huang, et al.
Published: (2017-03-01)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
by: Zu-Yau Lin, et al.
Published: (2023-10-01)

The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases
by: Yi-Hung Lin, et al.
Published: (2016-07-01)

Alström Syndrome with Acute Pancreatitis: A Case Report
by: Wen-Chih Wu, et al.
Published: (2003-07-01)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
by: Ching-I Huang, et al.
Published: (2023-06-01)

Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes
by: Tyng‐Yuan Jang, et al.
Published: (2022-09-01)

Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA−1273
by: Po-Hsu Su, et al.
Published: (2021-11-01)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2019-01-01)

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
by: Ming-Lung Yu, et al.
Published: (2018-06-01)